Liraglutide 3 mg for Knee Osteoarthritis

NCT02905864 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication liraglutide 3 mg, which is approved for weight loss, can help reduce body weight in people who have both knee osteoarthritis and obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 150 people Planned (estimated).

Who can join Ages 18–74 · all sexes

Timeline Started 2016-11 · est. completion 2019-03

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02905864 ↗

Description as written by the study sponsor.

A randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis. Patients will be subjected to a run-in diet intervention phase (week -8 to 0) including a low-calorie diet and dietetic counselling. At week 0 patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.

Treatments tested

Liraglutide 3 mg (Saxenda) Drug
Liraglutide 3 mg placebo Drug

Main thing measured	Change in body weight
Sponsor	Henrik Gudbergsen
Conditions studied	Osteoarthritis, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02905864 ↗